
Progress In Endovascular Treatment Of
Type A Aortic Dissections (TAADs) In 2024:
What Is Here And What Is Coming:
Experience With Ascending Aortic
Endografting Including The Gore Device In
The ARISE II Trial

Eric E. Roselli, MD
Chief, Adult Cardiac Surgery
Surgical Director, Aorta Center
Heart and Vascular Institute, Cleveland Clinic

Cleveland Clinic

## **Disclosures** Artivion Consultant, Investigator, Inventor Cook Speaker, Investigator Corcym Consultant, Investigator Edwards Lifesciences Consultant, Speaker Medtronic Speaker, Investigator Terumo Aortic Speaker, Investigator WL Gore Consultant, Investigator Off-label and Investigational use of devices discussed Cleveland Clinic














ARISE II Pivotal Study Design			
	Primary Arm: N=70	Secondary Arm: N=50 (min) N=150 (max)	Surgical Follow-up Cohort N=50 (min) N=150 (max)
Procedure / Devices	ASG Device Alone	ASG Device + TBE Device (CTAG as needed)	Open surgical repair
Patient Characteristics	High-risk Surgical Patient	High-risk Surgical Patient	High-risk Surgical Patient not meeting requirements for enrollment in primary or secondary arm
Disease States	Isolated aortic lesion of ascending aorta that can be treated with ASG device alone (aneurysms, pseudoaneurysms, PAU)	Isolated aortic lesion or chronic dissection (de novo or residual) that requires treatment with ASG device and distal extension with the TBE Device and/or the CTAG Device	Same as primary and secondary (Anatomic Screen Fail)
Cleveland Clinic  Products listed are investigational and may not be available in all markets. Limited by United States law to investigational use only			

